RxDoctor Payments Data

Craig Brown, MD

Pulmonary Disease · Gainesville, GANPI 1063680882

Payments from drug & device makers

$4,705in general payments, 2019–2025

Across 33 payments — averaging $142.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • GSK$213
  • United Therapeutics Corporation$127
  • Electromed, Inc.$53
  • Insmed, Inc.$43
  • Genentech USA, Inc.$40
  • plus $136 from 6 others

What the payments were for

  • Travel & lodging$1,04022%
  • Food & beverage$57612%
  • Education$3,08966%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,705 in reported general payments places this provider in the 45th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$374,861
Medicare patients
831
Services billed
8,686

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter692$655,314
OpsumitMacitentan29$473,752
AdempasRiociguat20$258,800
OfevNintedanib Esylate17$212,395
Breo ElliptaFluticasone/Vilanterol370$199,012
Breztri AerosphereBudesonide/Glycopyr/Formoterol157$143,986
NucalaMepolizumab12$131,016
Spiriva RespimatTiotropium Bromide137$116,285
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr120$85,839
Stiolto RespimatTiotropium Br/Olodaterol Hcl114$84,833
Dupixent SyringeDupilumab22$82,310
SymbicortBudesonide/Formoterol Fumarate154$47,921
Spiriva HandihalerTiotropium Bromide51$45,439
Incruse ElliptaUmeclidinium Bromide88$34,195
Advair HfaFluticasone Propion/Salmeterol52$26,040

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta$213$1,127,6341,358 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$34$430,997291 claims
BayerAdempas$14$258,80020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →